Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0Z4JL
|
|||
Former ID |
DNC007341
|
|||
Drug Name |
KKHT-10618
|
|||
Synonyms |
KKHT-10618; CHEMBL225601; SCHEMBL8230918; BKSKSEWIBBBRSQ-UHFFFAOYSA-N; BDBM50196465; 3-(4-chlorobenzyl)-2,4-dioxo-N-(2-(piperidin-1-yl)ethyl)-1,2,3,4-tetrahydroquinazoline-7-carboxamide; 3-(4-Chloro-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-quinazoline-7-carboxylic acid (2-piperidine-1-yl-ethyl)-amide
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C23H25ClN4O3
|
|||
Canonical SMILES |
C1CCN(CC1)CCNC(=O)C2=CC3=C(C=C2)C(=O)N(C(=O)N3)CC4=CC=C(C=C4)Cl
|
|||
InChI |
1S/C23H25ClN4O3/c24-18-7-4-16(5-8-18)15-28-22(30)19-9-6-17(14-20(19)26-23(28)31)21(29)25-10-13-27-11-2-1-3-12-27/h4-9,14H,1-3,10-13,15H2,(H,25,29)(H,26,31)
|
|||
InChIKey |
BKSKSEWIBBBRSQ-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) | Target Info | Inhibitor | [1] |
KEGG Pathway | MAPK signaling pathway | |||
Calcium signaling pathway | ||||
Circadian entrainment | ||||
Type II diabetes mellitus | ||||
Panther Pathway | Endogenous cannabinoid signaling | |||
GABA-B receptor II signaling | ||||
Nicotine pharmacodynamics pathway | ||||
Pathwhiz Pathway | Muscle/Heart Contraction | |||
Pathway Interaction Database | Regulation of nuclear beta catenin signaling and target gene transcription | |||
Reactome | NCAM1 interactions | |||
WikiPathways | NCAM signaling for neurite out-growth | |||
Nicotine Activity on Chromaffin Cells |
References | Top | |||
---|---|---|---|---|
REF 1 | Novel T-type calcium channel blockers: dioxoquinazoline carboxamide derivatives. Bioorg Med Chem. 2007 Jan 1;15(1):365-73. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.